Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708637 · ClinicalTrials.gov registry record · Phase 4
Ocular Safety and Usability Study for FYB203 PFS
A Phase 4 study of Age-related Macular Degeneration and Diabetic Macular Edema, sponsored by Formycon.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT06708637 is a Phase 4 study of Age-related Macular Degeneration and Diabetic Macular Edema that has completed, run by Formycon. The registered enrollment target is 30 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT06708637, a Phase 4 study of Age-related Macular Degeneration and Diabetic Macular Edema, has completed, sponsored by Formycon.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
The objective of the study is to assess the ocular safety of the FYB203 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
Conditions Studied
Interventions
- DRUG FYB203 2 mg (0.05 mL of 40 mg/mL)
Study Locations (4)
California
- Research Site - Campbell
- Research Site - Long Beach
- Research Site - Redlands
Oregon
- Research Site - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06708637
The ClinicalTrials.gov registry entry for NCT06708637 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower). The listed sponsor is Formycon, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which FYB203 2 mg (0.05 mL of 40 mg/mL) is the first listed.
NCT06708637 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, Oregon.
Frequently Asked Questions
What is clinical trial NCT06708637 about?
NCT06708637 is a clinical study titled "Ocular Safety and Usability Study for FYB203 PFS". The objective of the study is to assess the ocular safety of the FYB203 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
What is the current status of trial NCT06708637?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2024-09-20. Estimated completion is 2024-10-08.
What conditions does trial NCT06708637 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion with Macular Edema.
What interventions are being tested in trial NCT06708637?
The interventions under investigation include: FYB203 2 mg (0.05 mL of 40 mg/mL) (DRUG).
Who is sponsoring clinical trial NCT06708637?
This trial is sponsored by Formycon, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06708637 being conducted?
This trial has 4 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ocular Safety and Usability Study for FYB201 PFS
COMPLETED · Phase 4
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
High Resolution Retinal Imaging
RECRUITING
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.